Drugs / pyridoxalated hemoglobin polyoxyethylene conjugate
pyridoxalated hemoglobin polyoxyethylene conjugate
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT00021502 | Mar 2001 → Aug 2003 | autoinflammatory syndrome | Apex Bioscience | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | pyridoxalated hemoglobin polyoxyethylene conjugate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00021502 ↗ |
| Known as | PHP | “pyridoxylated hemoglobin polyoxyethylene conjugate (PHP) administered by continuous intravenous (IV) infusion” NCT00021502 ↗ |
| Known as | pyridoxalated hemoglobin polyoxyethylene | “hemoglobin-based nitric oxide scavenger, pyridoxalated hemoglobin polyoxyethylene (PHP), in patients with distributive shock” PMID 18552688 ↗ Jul 2008 |
| Action | Inhibit | “PHP selectively scavenges excess nitric oxide (NO)” NCT00021502 ↗ |
| Modality | Protein / enzyme biologic | “PHP is a human-derived chemically modified hemoglobin preparation.” NCT00021502 ↗ |
| Route | Intravenous | “administered by continuous intravenous (IV) infusion” NCT00021502 ↗ |